Medl.Si

MEDL.SI has a negative equity position of -5,479,950 MYR, indicating a significant financial challenge. The company's liquidity is further strained with a current ratio of 0.13, suggesting it has limited ability to meet short-term obligations. The negative operating cash flow of -3,976,600 MYR and free cash flow of -3,815,860 MYR highlight the company's inability to generate positive cash from operations.

In terms of profitability, MEDL.SI is performing poorly. The company reported a net loss of -3,857,590 MYR, and its return on equity is 70.39%, which is unusually high due to the negative equity base. The return on assets is -4.56%, indicating that the company is not effectively utilizing its assets to generate profit.

The company's revenue is concentrated in a single segment, as disclosed in its financials, with no specific geographic breakdown provided. This lack of diversification increases the risk associated with its revenue streams.

MEDL.SI's growth trajectory is negative, with a significant decline in operating income and net income. The company's capital expenditure of -3,850 MYR is minimal, suggesting a lack of investment in future growth.

The company faces significant liquidity and solvency risks, as evidenced by its negative net cash position after subtracting total debt. The dilution risk is currently low, but the company's financial instability could lead to future dilution if it needs to raise additional capital.

Recent filings and transcripts indicate that the company is struggling with financial performance and may need to take corrective actions to improve its financial health. The company's management has not provided specific details on how it plans to address these challenges.